Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are ...

Eli Lilly & Co. raised its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Pharma giant Eli Lilly tapped Walmart to offer in-store pickups of Zepbound vials, marking the first retail collaboration for ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

Shares of Eli Lilly rose nearly 4% in premarket trading on Thursday after the pharmaceutical company reported third-quarter ...